



EHDN Clinical Research Congress 2026 22nd – 24th October 2026, Kraków, Poland

**Preliminary programme*

THURSDAY, 22nd OCTOBER, 2026

07:30 – 08:30 REGISTRATION DESK

08:30 – 09:00 WELCOME AND INTRODUCTION

Chaired by Patrick Weydt, Åsa Petersén, Cristina Sampaio and Danuta Lis

09:00 – 09:45 PLENARY SESSION I: HD Burden - Family and Patient Perspective

Chaired by Åsa Petersén

Speakers: Charlotte Spearing, Greg Witkowski and William Gray

09:45 – 10:30 PLENARY SESSION II: Navigating the Therapeutic Pipeline in Huntington's Disease

Chaired by Swati Sathe and Pavlina Stefanova-Konstantinova

1. The Race to treat Huntington's disease: where have we come over the past decade

Anne Rosser

2. Future Challenges and Opportunities in the Clinical Development of Huntington's Disease Therapies

Cristina Sampaio

10:30 – 11:00 **BREAK**

11:00 – 12:00 PARALLEL SESSIONS I

A. Psychological interventions in Huntington's Disease: a transdiagnostic perspective

Chaired by Docia Demmin and Lucienne van der Meer

1. Keeping Yourself in Mind: Acceptance and Commitment Therapy programmes for people affected by Huntington's Disease

Sarah Gunn

2. Resilient together-ALS: an early dyadic intervention for patients and their informal care-partners

Christina Rush

3. Reducing anxiety in people with HD using a guided self-help intervention

Jane Simpson and Maria Dale

B. Advanced Therapies/Clinical Trials TF

Chaired by Patrick Weydt and Ruben van Eijk

1. Lessons and innovations in clinical trials for Amyotrophic Lateral Sclerosis

Ruben van Eijk

2. Looking back - looking forward: insights into clinical trial design and determination of clinical meaningfulness

Michael Hayden

3. Placebo-controlled surgical trials: an ethical overview

Cindy Towns

12:00 – 13:30 **LUNCH and POSTER VIEWING**



13:30 – 14:30

PARALLEL SESSIONS II

A. Digital Biomarkers and Artificial Intelligence

Chaired by Jean-Marc Burgunder and Matt Roche

1. **Sensitivity, Validity, and Utilization of the HDDMS in Clinical Trials**
Jonas Dorn
2. **Q-Motor results from AMT-130**
David Margolin
3. **Talk III**
Run Zhuang
4. **Panel Discussion and Q&A**

B. Social Cognition

Chaired by Sarah Mason and Rebecca Fuller

1. **Reading minds missing people: Ecological validity problem in social cognition**
Erin Heerey
2. **Cling Film, Text Messages and Work - Three ethnographic stories of early social cognitive change in Huntington's disease**
Alex Fisher
3. **Talk III**
TBA
4. **Panel Discussion**

14:30 – 14:35

Transition BREAK

14:35 – 15:15

EHDN BUSINESS MEETING

Chaired by Patrick Weydt and Ása Petersén

15:15 – 15:45

BREAK

15:45 – 16:45

KEYNOTE LECTURE I: Genetic Testing and Genetic Modifiers

Chaired by Nayana Lahiri and Hoa Huu Phuc Nguyen

Speaker: Alexandra Durr

16:45 – 17:45

DEBATE: Implementation of Genetic Modifier Data into Clinical Practice – Are we there, yet?

Chaired by Nayana Lahiri and Hoa Huu Phuc Nguyen

Speaker: Michael Hayden, Alexandra Durr and Darren Monckton

17:45 – 21:00

NETWORKING EVENING

Posters, art exhibition, finger food & drinks



FRIDAY, 23rd OCTOBER, 2026

08:00 – 08:45 **PLENARY SESSION III: Access and Affordability for the HD Community**

Chaired by Hugh Rickards and Jenna Heilman

3. **HEATED (Huntington's Equal Access to Effective Drugs). The story so far.**
Hugh Rickards
4. **What are the barriers to access to effective drugs in HD and how do we overcome them?**
Josie Godrey
5. **Access to effective HD drugs: the global perspective**
Nacho Sanjuan

08:45 – 09:45 **UPDATE ON ONGOING CLINICAL TRIALS**

Chaired by Jenny Townhill and Ralf Reilmann

1. **Alnylam**
Sarah Tabrizi
2. **VICO Therapeutics**
Scott Schobel
3. **Skyhawk Therapeutics**
Meghan Miller and Pannie Trifillis
4. **Panel Discussion and Q&A**

09:45 – 10:00 **BREAK**

10:00 – 11:00 **PARALLEL SESSIONS III**

A. Modifiers of Huntington's Disease: Genetic, Biological, and Preclinical Perspectives

Chaired by Marta Biagioli and Vahri Beaumont

1. **PMS1/MLH1 variants and drugging the PMS1 ATPase site**
Tom Massey
2. **MED15 as a Non-MMR Modifier of Huntington's Disease**
Mahmoud Pouladi
3. **hiPSC cell models**
Mike Flowers

B. Glymphatic Imaging

Chaired by Daniel Claassen and Andrew Wood

1. **Imaging human glymphatic function with intrathecal contrast: from method to clinical readout**
Kristian Eide
2. **Talk II**
TBA
3. **Imaging the glymphatic system in Huntington's disease and neurodegeneration: implications for monitoring and neurotherapeutics**
Manus Donahue

11:00 – 11:30 **BREAK**

11:30 – 12:30 **KEYNOTE LECTURE II: The ubiquitin proteolytic system - from a hypothetical assumption of why it should exist to human diseases and drug development**

Chaired by Hoa Huu Phuc Nguyen

Speaker: Prof. Dr. Aaron Ciechanover (Nobel Prize Winner for Chemistry 2004)



- 12:30 – 14:30 **LUNCH, POSTER VIEWING and SPECIAL SESSIONS**
- | | | |
|---|--|--|
| <p>a. HDYO and EHA
13:15–14:15
Chaired by Jenna Heilman and Astri Arnesen</p> | <p>b. EHDN Fellowship
13:15–14:15
Chaired by Juliana Bronzova and Fionnuala Margreiter</p> | <p>c. Local Language Session
13:00–15:30
Chaired by Danuta Lis and Daniel Zielonka</p> |
|---|--|--|
- 14:30 – 15:30 **SHORT COMMUNICATIONS I**
Presentation of selected abstracts
Chaired by Davina Hensman Moss and Jiří Klempř
- 15:30 – 16:30 **PLENARY SESSION IV: Advanced Biomarkers**
Chaired by Hilary Wilkinson and Niels Skotte
1. **Lipidomics and new biomarkers**
William Griffiths
 2. **PENK & NEFL**
Niels Skotte and Hilary Wilkinson
 3. **HD YAS 3.0**
Rachael Scahill
- 16:30 – 17:00 **BREAK**
- 17:00 – 18:00 **PANEL DISCUSSION: Clinical Trial Communications in Context - Rules, Responsibilities, and Community Expectations**
Chaired by Emily Gantman and Ed Wild
Panel: Charlotte Spearing, Mai-Lise Nguyen, Rachel Harding and David Anderson

SATURDAY, 24th OCTOBER, 2026

- 08:30 – 09:15 **EHDN LIGHTNING PRESENTATIONS**
Chaired by Duncan McLauchlan and Agnieszka Fiszer
1. **Lightning Presentation on awarded EHDN Strategic Funds**
Nayana Lahiri, Una Jones and Cheney Drew
 2. **Talk II**
Véronica Ines Brito
 3. **Talk III**
Jang-Ho Cha
- 09:15 – 10:15 **PLENARY SESSION V: Efficacy Demonstration - Standards, Measures and Endpoints**
Chaired by Ahmad Aziz and Jamie Hamilton
4. **Analysis of Enroll-HD TMS training data**
Matt Roche
 5. **Talk II**
Angelika Caputo
 6. **MCID within the context of other Neurodegenerative disorders**
Glenn Stebbins
- 10:15 – 10:45 **BREAK**
- 10:45 – 11:45 **SHORT COMMUNICATIONS II**
Presentation of selected abstracts
Chaired by Mayke Oosterloo and Arun Karpur



- 11:45 – 12:45 **From Clinical Trial Progress and Regulatory Perspectives**
Chaired by Bernhard Landwehrmeyer and Daniel Weintraub
- 1. Regulatory perspectives on trial innovation and clinical meaningful outcomes**
Elena Hernández Martínez de Lapiscina (15min)
 - 2. Talk II**
David Margolin (15min)
 - 3. Talk III**
Beth Borowsky (15min)
 - 4. Panel Discussion and Q&A**
Elena Hernández Martínez de Lapiscina, David Margolin, Beth Borowsky, Anne Rosser and Dina De Sousa (15min)
- 12:45 – 13:10 **SUMMARY AND POSTER AWARD**
Chaired by Nayana Lahiri and Hoa Huu Phuc Nguyen
- 13:10 – 13:15 **FAREWELL**
Chaired by Patrick Weydt and Cristina Sampaio